Loading
GeoVax Labs, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SPENCER JOHN N JR, was filed 20 Oct 2025.
GeoVax Labs, Inc.: what insiders have been doing
GeoVax Labs, Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). GeoVax Labs, Inc. has had no insider filing for more than a year; the last one goes back to 20 October 2025.
Looking back to 2020, when coverage begins, insiders filed 28 purchases and no sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 2.5 m USD and net income at -21.5 m USD.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
28
Thresholds
n/a
Buy Volume
€1M
28 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleJOHN N. SPENCER Jr.2 buys
David A. Dodd1 buy
John W. Sharkey1 buy
Kelly T. McKee Jr.1 buy
Mark Reynolds1 buy
Since the insiders bought
- -98.4%Entry US$14.48 · Close 20 Oct 2026 US$0.23
- -95.6%Entry US$17.00 · Close at T+365 US$0.75
- -95.0%Entry US$25.50 · Close at T+365 US$1.28
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.24
Analyst consensus
2 analysts1.50/5
US$10.00Target US$10.00(+4103%)US$10.00
Income statement
RevenueUS$2.5M
EBITDA-US$21.4M-860% margin
Net income-US$21.5M-862.3% margin
Valuation
P/Book1.0x
Beta3.69
Balance sheet & cash
Market capUS$2.4M
Total debtUS$843.2k
Free Cash Flow-US$21.5M
Debt / Equity18%
Profitability & ownership
ROE-891.6%
ROA-256.8%
% insiders0.0%
% institutions9.8%
Last declaration on 20 October 2025
Declarations28 total
10,000 shares@ US$0.549835.1% of flowCommon StockSEC:0001437749-25-031314:0
Canonical exit: 15 Jan 2026 (T+90)
1,107 shares@ US$0.672.8% of flowCommon StockSEC:0001437749-25-025690:0
Canonical exit: 5 Nov 2025 (T+90)
10,000 shares@ US$0.9864.9% of flowCommon StockSEC:0001437749-25-011750:0
Canonical exit: 9 Jul 2025 (T+90)
6,000 shares@ US$0.9987.1% of flowCommon StockSEC:0001437749-25-011658:0
Canonical exit: 9 Jul 2025 (T+90)
10,000 shares@ US$1.0816.0% of flowCommon StockSEC:0001437749-25-010482:0
Canonical exit: 30 Jun 2025 (T+90)
6,800 shares@ US$1.079931.9% of flowCommon StockSEC:0001437749-25-010179:0
Canonical exit: 29 Jun 2025 (T+90)
8,000 shares@ US$1.9522.9% of flowCommon StockSEC:0001437749-24-025953:0
Canonical exit: 7 Nov 2024 (T+90)
8,209 shares@ US$2.2721.6% of flowCommon StockSEC:0001437749-24-005209:1
Canonical exit: 22 May 2024 (T+90)
520 shares@ US$2.151.7% of flowCommon StockSEC:0001437749-24-005209:0
Canonical exit: 21 May 2024 (T+90)
2,000 shares@ US$2.7724.2% of flowCommon StockSEC:0001437749-24-003380:0
Canonical exit: 7 May 2024 (T+90)
6,944 shares@ US$0.3610.2% of flowCommon StockSEC:0001437749-23-035306:0
Canonical exit: 21 Mar 2024 (T+90)
9,653 shares@ US$0.5221.2% of flowCommon StockSEC:0001437749-23-026935:0
Canonical exit: 24 Dec 2023 (T+90)
35,087 shares@ US$0.5729.7% of flowCommon StockSEC:0001437749-23-024763:0
Canonical exit: 23 Nov 2023 (T+90)
10,000 shares@ US$0.517922.4% of flowCommon StockSEC:0001437749-23-024227:0
Canonical exit: 16 Nov 2023 (T+90)
32,000 shares@ US$0.638929.7% of flowCommon StockSEC:0001437749-23-011000:0
Canonical exit: 23 Jul 2023 (T+90)
8,000 shares@ US$0.6321.6% of flowCommon StockSEC:0001437749-23-010776:0
Canonical exit: 19 Jul 2023 (T+90)
10,000 shares@ US$1.1049.3% of flowCommon StockSEC:0001437749-22-022942:0
Canonical exit: 20 Dec 2022 (T+90)
1,000 shares@ US$0.8212.9% of flowCommon StockSEC:0001437749-22-016567:0
Canonical exit: 29 Sept 2022 (T+90)
4,464 shares@ US$1.120.15% mcap21.1% of flowCommon StockSEC:0001437749-22-016072:0
Canonical exit: 25 Sept 2022 (T+90)
10,000 shares@ US$1.210.36% mcap50.7% of flowCommon StockSEC:0001437749-22-015552:0
Canonical exit: 19 Sept 2022 (T+90)
9,722 shares@ US$0.7229.7% of flowCommon StockSEC:0001437749-22-011257:0
Canonical exit: 3 Aug 2022 (T+90)
4,999 shares@ US$0.7114.9% of flowCommon StockSEC:0001437749-22-011137:0
Canonical exit: 2 Aug 2022 (T+90)
21,024 shares@ US$5.00Common StockSEC:0001437749-20-020451:0
Canonical exit: 28 Dec 2020 (T+90)
53,925 shares@ US$5.00Common StockSEC:0001437749-20-020452:0
Canonical exit: 28 Dec 2020 (T+90)
11,987 shares@ US$5.00Common StockSEC:0001437749-20-020450:0
Canonical exit: 28 Dec 2020 (T+90)
25 of 28 declarations
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biopharmaceutical company focused on developing vaccines and therapies for infectious diseases and cancers. It utilizes its vaccine technology platform to create innovative solutions.
